Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862358 | 0.89 | TACR1 (0.72) | TACR1 | |
| SCHEMBL4111340 | 0.87 | TACR1 (0.70) | TACR1 | |
| SCHEMBL4125622 | 0.87 | TACR1 (0.72) | TACR1 | |
| SCHEMBL6872837 | 0.86 | TACR1 (0.54) | TACR1 | |
| Hydrochloric Acid SCHEMBL5741520 | 0.86 | TACR1 (0.71) | TACR1 | |
| SCHEMBL6021041 | 0.86 | TACR1 (0.78) | TACR1 | |
| SCHEMBL905330 | 0.84 | TACR1 (1.00) | TACR1 | |
| SCHEMBL29467378 | 0.84 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL905341 | 0.83 | TACR1 (0.98) | TACR1 | |
| SCHEMBL6637377 | 0.83 | TACR1 (0.83) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | claimed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | claimed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | claimed |
| EP-1157005-B1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | claimed |
| EP-1157005-A1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-28 | — | — | EP | claimed |
| US-6225316-B1 | GOOD AFFINITY TO THE NK-1 RECEPTOR. | HOFFMANN-LA ROCHE INC. | 2001-05-01 | — | — | US | claimed |
| WO-2000050401-A1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-31 | — | — | WO | claimed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | disclosed |
| US-9186404-B2 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2015-11-17 | — | — | US | disclosed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | disclosed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | disclosed |
| EP-1157005-B1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1157005-A1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-28 | — | — | EP | disclosed |
| US-6225316-B1 | GOOD AFFINITY TO THE NK-1 RECEPTOR. | HOFFMANN-LA ROCHE INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2000050401-A1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885 |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.